Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder

被引:233
作者
Yonkers, KA
Brown, C
Pearlstein, TB
Foegh, M
Sampson-Landers, C
Rapkin, A
机构
[1] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT 06510 USA
[2] Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, New Haven, CT 06510 USA
[3] Univ Tennessee, Ctr Hlth Sci, Dept Pharm, Memphis, TN 38163 USA
[4] Univ Tennessee, Ctr Hlth Sci, Dept Obstet & Gynecol, Memphis, TN 38163 USA
[5] Univ Tennessee, Ctr Hlth Sci, Dept Psychiat, Memphis, TN 38163 USA
[6] Brown Med Sch, Dept Psychiat & Human Behav, Providence, RI USA
[7] Berlex Labs Inc, Montville, NJ USA
[8] Univ Calif Los Angeles, Dept Obstet & Gynecol, Los Angeles, CA 90024 USA
关键词
D O I
10.1097/01.AOG.0000175834.77215.2e
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective: To compare the efficacy of a new low-dose oral contraceptive pill (OCP) formulation with placebo in reducing symptoms of premenstrual dysphoric disorder. Methods: This multicenter, double-blind, randomized clinical trial consisted of 2 run-in and 3 treatment cycles with daily symptom charting; 450 women with symptoms of premenstrual dysphoric disorder were randomized to either placebo or an OCP formulation containing drospirenone 3 mg and ethinyl estradiol 20 mu g. Hormones were administered for 24 days, followed by 4 days of inactive pills (24/4). Results: Scores on the total Daily Record of Severity of Problems decreased by -37.49 in the drospirenone/ethinyl estradiol group and by -29.99 in the placebo group (ad-justed mean difference -7.5, 95% confidence interval vertical bar Cl vertical bar -11.2 to -3.8; P < .001 by rank analysis of covariance). Mood symptom scores were reduced by -19.2 and -15.3 in active-treatment and placebo groups, respectively (adjusted mean difference -3.9, 95% Cl -5.84 to -2.01; P = .003); physical symptom scores were reduced by -10.7 and -8.6 in active-treatment and placebo groups, respectively (ad-justed mean difference -2,1, 95% Cl 3.3 to -0-95; P < .001); and behavioral symptom scores were reduced by -7.7 and -6.2 in active-treatment and pla(ebo groups, respectively (adjusted mean difference -1.5, 95%, Cl -2.251 to -0.727; P < .001. Response, definod as a 501% decrease in daily symptom scores, OCCUrred in 48% of the activetreatment group and 36% of the placebo group (relative risk 1.7, 95%, Cl 1.1 to 2.6; P = .015) and corresponds to a number-needed-to-treat of 8 patients. Conclusion: A 24/4 regimen of drospirenone 3 mg and ethinyl estradiol 20 mu g improves symptoms associated with premenstrual dysphoric disorder.
引用
收藏
页码:492 / 501
页数:10
相关论文
共 31 条
[1]  
*AM PSYCH ASS, 2000, DIAGN STAT MAN MENT, P771
[2]   Evaluation of contraceptive efficacy and cycle control of a transdermal contraceptive patch vs an oral contraceptive - A randomized controlled trial [J].
Audet, MC ;
Moreau, M ;
Koltun, WD ;
Waldbaum, AS ;
Shangold, G ;
Fisher, AC ;
Creasy, GW .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (18) :2347-2354
[3]   Efficacy and safety of a low-dose 24-day combined oral contraceptive containing 20 μg ethinylestradiol and 3 mg drospirenone [J].
Bachmann, G ;
Sulak, PJ ;
Sampson-Landers, C ;
Benda, N ;
Marr, J .
CONTRACEPTION, 2004, 70 (03) :191-198
[4]   ORAL-CONTRACEPTIVES IN PREMENSTRUAL-SYNDROME - A RANDOMIZED COMPARISON OF TRIPHASIC AND MONOPHASIC PREPARATIONS [J].
BACKSTROM, T ;
HANSSONMALMSTROM, Y ;
LINDHE, BA ;
CAVALLIBJORKMAN, B ;
NORDENSTROM, S .
CONTRACEPTION, 1992, 46 (03) :253-268
[5]  
Backström T, 2003, CNS DRUGS, V17, P325
[6]  
BROWN CS, 1994, OBSTET GYNECOL, V84, P779
[7]   Paroxetine controlled release for premenstrual dysphoric disorder: A double-blind, placebo-controlled trial [J].
Cohen, LS ;
Scares, CN ;
Yonkers, KA ;
Bellew, KM ;
Bridges, IM ;
Steiner, M .
PSYCHOSOMATIC MEDICINE, 2004, 66 (05) :707-713
[8]   Premenstrual daily fluoxetine for premenstrual dysphoric disorder: A placebo-controlled, clinical trial using computerized diaries [J].
Cohen, LS ;
Miner, C ;
Brown, E ;
Freeman, EW ;
Halbreich, U ;
Sundell, K ;
McCray, S .
OBSTETRICS AND GYNECOLOGY, 2002, 100 (03) :435-444
[9]  
ENDICOTT J, 1993, PSYCHOPHARMACOL BULL, V29, P321
[10]   A twelve-month comparative clinical investigation of two low-dose oral contraceptives containing 20 mu g ethinylestradiol 75 mu g gestodene and 30 mu g ethinylestradiol 75 mu g gestodene, with respect to efficacy, cycle control, and tolerance [J].
Endrikat, J ;
Muller, U ;
Dusterberg, B .
CONTRACEPTION, 1997, 55 (03) :131-137